In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals (SPPI), with a price target of $12.00. The company’s shares closed last Thursday at $3.51.
According to TipRanks.com, White is a 5-star analyst with an average return of 27.0% and a 50.4% success rate. White covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Allena Pharmaceuticals, and TRACON Pharmaceuticals.
Currently, the analyst consensus on Spectrum Pharmaceuticals is a Strong Buy with an average price target of $11.75, implying a 233.8% upside from current levels. In a report issued on October 26, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.57 and a one-year low of $1.74. Currently, Spectrum Pharmaceuticals has an average volume of 2.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
